CrossRef Unraveling the tapestry: Lessons from multi-omics and spatial biology in hepatocellular cancer Dawiyat Massoudi, Ankit Srivastava, Renumathy Dhanasekaran Hepatology .2026;[Epub] CrossRef Antibiotic Use Linked to Worse Outcomes in Patients With Gastrointestinal and Liver Cancer on Immune Checkpoint Inhibitors: A Meta-Analysis Mohammad Saeid Rezaee-Zavareh, Hamidreza Karimi-Sari, Peyvand Parhizkar Roudsari, Osama Khattab, Abdelrahman M
With well over 30 million people in the United States diagnosed with T2DM,20 according to the 2020 National Diabetes Statistics Report, the GLP-1 RAs have shown significant benefits beyond solely lowering A1C, and the trials for SGLT-2 inhibitors show an overall benefit for hospitalization and heart failure, in addition to renal protection, offering promise in not only managing diabetes but also in preventing microvascular and macrovascular complications
Common starting doses include: 0.5-1 mg weekly: Recommended for patients sensitive to side effects or new to GLP-1 medications 2.5 mg weekly: A standard starting dose balancing effectiveness and tolerability Lower starting doses allow the body to adjust gradually, reducing gastrointestinal side effects like nausea or dizziness that often occur when beginning treatment
Macronutrient diet intake of the lethal yellow agouti (Ay/a) mouse
